<?xml version="1.0" encoding="UTF-8"?>
<ref id="B144-biomedicines-08-00060">
 <label>144.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Morris</surname>
    <given-names>D.G.</given-names>
   </name>
   <name>
    <surname>Feng</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>DiFrancesco</surname>
    <given-names>L.M.</given-names>
   </name>
   <name>
    <surname>Fonseca</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Forsyth</surname>
    <given-names>P.A.</given-names>
   </name>
   <name>
    <surname>Paterson</surname>
    <given-names>A.H.</given-names>
   </name>
   <name>
    <surname>Coffey</surname>
    <given-names>M.C.</given-names>
   </name>
   <name>
    <surname>Thompson</surname>
    <given-names>B.</given-names>
   </name>
  </person-group>
  <article-title>REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin
   <sup>Â®</sup>) in patients with advanced solid tumors
  </article-title>
  <source>Investig. New Drugs</source>
  <year>2013</year>
  <volume>31</volume>
  <fpage>696</fpage>
  <lpage>706</lpage>
  <pub-id pub-id-type="doi">10.1007/s10637-012-9865-z</pub-id>
  <pub-id pub-id-type="pmid">22886613</pub-id>
 </element-citation>
</ref>
